Growth Hormone Axis

Overview

The growth hormone (GH) axis — also termed the somatotropic axis — is a central neuroendocrine system that regulates somatic growth, body composition, metabolic homeostasis, and tissue repair throughout life. It operates through a hierarchical cascade: the hypothalamus releases stimulatory and inhibitory signals that control growth hormone secretion from the anterior pituitary, and GH in turn stimulates the production of insulin-like growth factor-1 (IGF-1), primarily in the liver.

This axis is the direct target of the largest class of peptides in the research and clinical peptide landscape. Growth hormone-releasing peptides (GHRPs), growth hormone-releasing hormone (GHRH) analogs, and ghrelin mimetics all act at various nodes of this axis. Understanding its architecture is essential for interpreting how these compounds work and why their effects differ.

How It Works

The Hypothalamic Level

The hypothalamus provides dual regulation of GH secretion through two opposing peptide signals:

GHRH (Growth Hormone-Releasing Hormone)

• Produced by neurons in the arcuate nucleus of the hypothalamus
• Released into the hypothalamic-hypophyseal portal blood system
• Binds GHRH receptors (GHRH-R) on somatotroph cells in the anterior pituitary
• Stimulates both GH synthesis and secretion
• GHRH receptor activation increases intracellular cAMP via Gs-protein coupling

Somatostatin (SST / SRIF)

• Produced by neurons in the periventricular nucleus of the hypothalamus
• Inhibits GH release from pituitary somatotrophs
• Acts through somatostatin receptors (SSTR1-5, particularly SSTR2 and SSTR5)
• Does not significantly affect GH synthesis — primarily controls the timing and amplitude of GH pulses
• Also inhibits TSH, insulin, glucagon, and numerous GI hormones

The interplay between GHRH and somatostatin generates the characteristic pulsatile pattern of GH secretion: GHRH pulses stimulate GH release when somatostatin tone is low (primarily during sleep), while rising somatostatin between pulses creates the troughs.

Ghrelin

• The "third regulator" — produced primarily in the stomach, with smaller amounts in the hypothalamus
• Binds the growth hormone secretagogue receptor (GHS-R1a) on pituitary somatotrophs
• Amplifies GH release synergistically with GHRH
• Also stimulates appetite and regulates energy balance
• GHS-R1a is the target of numerous synthetic GH secretagogues (GHRPs, ghrelin mimetics)

The Pituitary Level

The anterior pituitary gland contains somatotroph cells (approximately 40-50% of anterior pituitary cell population) that synthesize, store, and secrete GH:

• GH is a 191-amino acid single-chain polypeptide (22 kDa dominant form)
• Secretion is pulsatile, with the largest pulse occurring during slow-wave sleep
• Daily GH output peaks during puberty and declines progressively with age (somatopause)
• GH secretion is influenced by: sleep, exercise, fasting, stress, sex steroids, and body composition

The Peripheral Level: GH Actions

GH exerts its effects through two mechanisms:

Direct effects — GH binds growth hormone receptors (GHR) on target tissues:

• Lipolysis in adipose tissue
• Insulin antagonism (diabetogenic effect)
• Stimulation of chondrocyte proliferation (direct)
• Hepatic glucose output

Indirect effects via IGF-1 — GH stimulates IGF-1 production:

• The liver produces approximately 75% of circulating IGF-1
• Local IGF-1 production also occurs in bone, muscle, and other tissues (autocrine/paracrine signaling)
• IGF-1 mediates most of GH's growth-promoting effects

IGF-1 and Its Binding Proteins

IGF-1 circulates primarily bound to IGF-binding proteins (IGFBPs):

• IGFBP-3 — Carries approximately 80% of circulating IGF-1 in a ternary complex with acid-labile subunit (ALS). This complex extends IGF-1's half-life from minutes to approximately 12-15 hours.
• IGFBP-1 through IGFBP-6 — Modulate IGF-1 bioavailability in tissue-specific ways
• Free (unbound) IGF-1 represents only about 1% of total circulating IGF-1 but is the biologically active fraction

IGF-1 signals through the IGF-1 receptor (IGF-1R), a tyrosine kinase receptor that activates:

• The PI3K/Akt pathway — cell survival and glucose metabolism
• The Ras-MAPK/ERK pathway — cell proliferation
• The mTOR pathway — protein synthesis and cell growth

Feedback Regulation

The GH axis employs multiple negative feedback loops:

1. IGF-1 → Hypothalamus — IGF-1 stimulates somatostatin release and inhibits GHRH secretion
2. IGF-1 → Pituitary — IGF-1 directly inhibits GH gene expression and secretion in somatotrophs
3. GH → Hypothalamus — GH stimulates somatostatin release (short-loop feedback)
4. GH → Pituitary — GH may directly inhibit its own secretion (ultra-short-loop feedback)

These feedback mechanisms ensure that GH and IGF-1 levels are maintained within a physiological range and prevent runaway stimulation.

Key Components

Component	Location	Role
GHRH	Hypothalamus	Stimulates GH release
Somatostatin	Hypothalamus	Inhibits GH release
Ghrelin	Stomach/hypothalamus	Amplifies GH release; appetite
GH	Anterior pituitary	Central effector hormone
GHR	Peripheral tissues	GH receptor
IGF-1	Liver (primarily)	Mediates GH growth effects
IGF-1R	Peripheral tissues	IGF-1 receptor (tyrosine kinase)
IGFBP-3/ALS	Circulation	IGF-1 carrier; extends half-life

Role in Peptide Research

The GH axis is the target of more research peptides than any other single pathway:

GHRH Analogs

Peptides such as CJC-1295 (with and without DAC), sermorelin, and tesamorelin act at the GHRH receptor on pituitary somatotrophs. They stimulate GH release in a physiological pulsatile pattern. CJC-1295 with Drug Affinity Complex (DAC) binds albumin, extending its half-life to approximately 6-8 days. Tesamorelin is FDA-approved for HIV-associated lipodystrophy.

Growth Hormone Secretagogues (GHRPs)

Ipamorelin, GHRP-2, GHRP-6, and hexarelin act at the ghrelin receptor (GHS-R1a). They stimulate GH release through a mechanism complementary and synergistic with GHRH. Ipamorelin is noted for its selectivity — it stimulates GH release without significantly affecting cortisol, ACTH, or prolactin at typical doses.

Combined Protocols

GHRH analogs and GHRPs are frequently discussed in combination (e.g., CJC-1295 no DAC + ipamorelin) because their synergistic mechanisms produce greater GH release than either alone. GHRH sets the amplitude, while GHRPs set the frequency and amplify the pulse.

BPC-157

BPC-157 has been shown to upregulate growth hormone receptor (GHR) expression in tendon fibroblasts, sensitizing local tissue to circulating GH and potentially amplifying the downstream effects of endogenous GH at injury sites (Chang et al., 2014).

MK-677 (Ibutamoren)

While technically a non-peptide ghrelin mimetic (an oral small molecule), MK-677 is frequently discussed alongside GH peptides. It activates GHS-R1a to stimulate sustained GH and IGF-1 elevation over 24 hours.

Clinical Significance

• Growth hormone deficiency — Both childhood and adult GHD are treated with recombinant GH (somatropin). GH secretagogue peptides represent an alternative approach that preserves physiological pulsatility and feedback regulation.
• Aging (somatopause) — GH and IGF-1 decline progressively after age 30, contributing to changes in body composition, bone density, and tissue repair capacity. The role of GH axis modulation in healthy aging remains actively debated.
• Acromegaly — GH excess from pituitary adenomas causes pathological tissue growth. Somatostatin analogs (octreotide, lanreotide) are used therapeutically to suppress GH secretion.
• Metabolic syndrome — The GH-IGF-1 axis interacts extensively with insulin signaling and lipid metabolism. GH deficiency is associated with increased visceral adiposity and cardiovascular risk.
• Cancer considerations — IGF-1 promotes cell proliferation through the mTOR pathway and inhibits apoptosis via PI3K/Akt. Elevated IGF-1 has been epidemiologically associated with increased risk of certain cancers, a consideration relevant to any intervention that raises IGF-1 levels.

Related Topics

• mTOR Pathway — Downstream effector of IGF-1 signaling for protein synthesis
• PI3K/Akt Pathway — Mediates IGF-1 receptor signaling
• HPA Axis — Cortisol interacts with GH axis; some GHRPs stimulate ACTH/cortisol
• HPG Axis — Sex steroids modulate GH secretion and IGF-1 production
• BPC-157 — Upregulates GH receptor expression locally